

Epidemiologia

lezione 0



Programma del corso 1

- *Introduzione: Epidemiologia finalità e definizioni*
- *Le radici dell'epidemiologia: sviluppo dei modelli di studio per indagare i fenomeni sanitari*
- *Misure epidemiologiche di frequenza e associazione*
- *Cause e determinanti della salute e delle malattie*
- *La distorsione sistematica dei risultati : i bias*
- *Disegno dello studio epidemiologico: classificazione*
- *Demografia (cenni)*
- *Sorveglianza e valutazione con dati ordinariamente disponibili – statistiche sanitarie correnti*
- *Lo studio dei trend*
- *Lo studio della distribuzione spaziale delle patologie e dei determinanti*
- [Epidemiologia delle malattie infettive]

Programma del corso 2

- Lo studio epidemiologico attraverso gli errori sistematici
 - *Bias di selezione*
 - *Bias di informazione*
 - *Confondimento*
- *Modifica di effetto o interazione*
- *Analisi statistica degli studi epidemiologici*
- Studi trasversali
- *Studi ecologici*
- *Studi di coorte*
- *Studi caso-controllo*
- *Altri disegni*
- *Studi sperimentali e meta-analisi*
- [Medicina preventiva]

Finalità del corso

- *Comprendere della rilevanza del metodo epidemiologico in medicina*
- *Acquisizione di capacità di lettura critica del disegno dello studio nella letteratura medica scientifica*
- *Definizione degli elementi di base per la realizzazione di ricerche in campo medico*
- *Analisi dei dati epidemiologici: comprensione e calcolo di misure epidemiologiche di base*

Testi in italiano

- *Rothman K J. Epidemiologia · Idelson-Gnocchi 2007*
- *Faggiano F, Donato F, Barbone F. Manuale di epidemiologia per la sanità pubblica.* Centro Scientifico Editore 2005
- *Beaglehole R, Bonita R, Kjellström T. Epidemiologia di base* Folini editore 2003
[\[http://whqlibdoc.who.int/publications/1997/887266031_ita.pdf\]](http://whqlibdoc.who.int/publications/1997/887266031_ita.pdf)
- Vineis P, Duca , Pasquini, Manuale di metodologia Epidemiologica, La Nuova Italia Scientifica, Roma, 1988
- [Ricciardi W et al. Igiene. Medicina Preventiva. Sanità Pubblica. · Idelson-Gnocchi 2013]
- [*La Rosa F.: Elementi di statistica medica ed epidemiologia.* Perugia, 2008]



Testi in lingua inglese

- Bhopal R. **Concepts of Epidemiology**: Integrating the ideas, theories, principles and methods of epidemiology. Oxford University Press 2008
- Kenneth J Rothman Sander Greenland Timothy L Lash. **Modern Epidemiology**. Lippincott 2008
- Gordis L. Epidemiology. Saunders Elsevier 2008
- *David E. Lilienfeld and Paul D. Stolley Foundations of Epidemiology. Oxford University Press 1994*

Complementari:

- Kelsey JL et al. Methods in Observational Epidemiology Oxford University Press 1996
- Selvin S. Epidemiologic Analysis: A Case-Oriented Approach

Nota

- La mancanza di testi universitari in italiano non è in alcun modo indice della natura accessoria o ornamentale della Metodologia epidemiologica

Altro

- Materiali: a disposizione per il download ma non sono pensati come prodotto autonomo...
- Presenza a lezione
- Spiegazioni
- Siti della rete:
 - <http://www.docstoc.com/docs/108111962/Variation-in-disease-by-time-place-and-person->
 - <http://www.teachepi.org/resources/bfiles.htm>
- [Tesine]
- [Auto valutazione ed esoneri]

Struttura

- Enunciazione teorica
- Esempio tratto dalla letteratura
- Analisi di articoli scientifici dedicati [limiti e difficoltà delle ricerche]
- Revisione della letteratura scientifica dedicata [processo di formazione delle conoscenze scientifiche]

Esame

4. (punti 2)

Gli studi di epidemiologia descrittiva

- a. sono caratterizzati dalla presenza di un gruppo di confronto o di controllo
- b. si basano sull'analisi di un evento morboso rispetto alle categorie di tempo, luogo, e caratteristiche personali
- c. possono essere suddivisi in studi trasversali, caso-controllo e di coorte
- d. non includono l'analisi della mortalità specifica per causa

Risposta multipla

Completa la definizione

17. (punti 2)

La _____ è un metodo sistematico che utilizza tecniche statistiche per combinare i risultati di studi indipendenti in modo da produrre una stima quantitativa complessiva dell'effetto di un particolare intervento o di una variabile su un esito definito.

19

Per studio caso-controllo a base primaria si intende uno studio in cui controlli ospedalieri sono selezionati in modo da essere rappresentativi della popolazione che ha dato origine ai casi

- a. Vero
- b. Falso

Vero o falso?

Fornisci una definizione sintetica e precisa di fattore di confondimento (max 5 punti)

Domanda aperta (breve)

Calcolare Rischio Relativo (RR) e Odds ratio (OR) di eccesso ponderale complessivo in base all'abitudine di praticare attività fisica agonistica (max 3 punti) utilizzando i dati riportati in tabella

Calcolare (portare calcolatrice)


Attività agonistica	BMI		
	Normale	Sovrappeso	Obeso
Si	40	10	5
No	50	30	10

Definizione 1

- Studio della distribuzione delle malattie nelle popolazioni e dei fattori che influenzano o determinano tale distribuzione
- Distribuzione delle malattie
- Popolazione
- Fattori che influenzano o determinano le malattie



popolazione



individuo




Scopi della epidemiologia

(in base alla definizione 1)

- Sorveglianza sanitaria: distribuzione delle malattie nelle popolazioni in base a Tempo, Luogo, Caratteristiche delle persone (tipicamente sesso ed età)
- Studio dell'eziologia delle malattie (base della prevenzione)

Principali cause di morte negli US nel 1900 e nel 2007

TOP TEN CAUSES OF DEATH, 1900 VERSUS 2007.



This graphic depicts the top ten causes of death in 1900 and in 2007. The average life expectancy in 1900 was 47.8 years. In 2007, it was 77.9 years.³⁶⁻³⁸




Figure 2. Mortality rates (age-adjusted data) in Italy from 1901 to 2000, year by year, for the main diseases responsible for death in the population. The reported diseases include infectious and parasitic diseases (INF), malignant tumors (TUM), cardiovascular diseases (CARD), cerebrovascular diseases (CER), respiratory diseases, including influenza (RESP), digestive system diseases (DIG), and accidents (ACC).


See text for the ICD-10 categories of diseases included in the analysis and for the procedure used for age-adjustment.

De Flora S, Quaglia A, Bennicelli C, Vercelli M. The epidemiological revolution of the 20th century. *FASEB J.* 2005;19:892-7.


Origini

- ἐπί(epi, "su") + δῆμος (dēmos, "popolo")
- Epidemia: verificarsi di casi di malattia in eccesso rispetto a quanto “normalmente atteso”
- Epidemiologia (studio delle epidemie)


Tasso per 100.000 abitanti - Popolazione standard Italia 2011




Tasso per 100.000 abitanti - Popolazione standard Italia 2011




Trend di incidenza e mortalità per cancro del polmone




Maschi



Femmine



Sopravvivenza complessiva per cancro del polmone e della prostata



Polmone maschi

Periodo sopravvivenza a 5a

1978-82: 11%

1994-98: 15%

1999-02: 14%

2003-05 14%

Prostata


Periodo sopravvivenza a 5a

1978-82: 39%

1994-98: 77%

1999-03: 88%

2004-08 92%




Rischio relativo di morte per periodo di diagnosi

Rischio relativo di morte per intervalli temporali rapportato al periodo 1994-2011. Trend di sopravvivenza con intervalli di confidenza




Maschi





Trend sopravvivenza relativa a 1, 3, 5 anni.




Maschi




Femmine





Terapia sistemica nel NSCLC



Cancro della mammella: Trend di incidenza e mortalità, tutte le età (tassi st. Umbria 2001)



Nella classe d'età screening (50-69 anni)







Figure 2 Incidence rates of gastric cancer in 1992 in selected regions and populations reported by population-based cancer registries. The incidence rates are age-standardised to the world population model.

Naohito Yamaguchi , Tadao Kakizoe **Synergistic interaction between Helicobacter pylori gastritis and diet in gastric cancer.** The Lancet Oncology Volume 2, Issue 2 2001 88 - 94

Luogo


Estimated incidence & mortality from gastric cancer in men, 2012








a



b



c



d

Gastric cancer
mortality in Italy
in
Estève J, Benhamou E,
Raymond L. Méthodes
statistiques en
épidémiologie descriptive.
INSERM Paris 1993

Figure 3.5 Mortalité par cancer de l'estomac – Italie – Sexe masculin – 1975-1977
a : SMR observés, b : ajustement linéaire,
c : ajustement quadratique, d : ajustement par un polynôme de degré 5
Source : Cislaghi et al. [2] et communication personnelle



L'esempio del cancro gastrico

1978-1982




1994-1998

1999-2003


MALE




FEMALE




Incidenza di cancro gastrico in Umbria



Mesotelioma in Umbria




SIR maschi




SIR femmine


La georeferenziazione dei casi




Analisi per sezione di censimento




Incidenza di cancro del polmone a Terni nel sesso femminile



Incidenza di cancro del polmone a Terni e comuni limitrofi nel sesso femminile



Tutti i casi




Solo le donne residenti da almeno 5 anni

Figure 1 Cancer rates in migrants become similar to those in the local population.

Cancer rates in 1990 among Japanese migrants to Hawaii, and around 1970 and 1990 in Japan (Osaka) and in Hawaiian Caucasians.


Peto J. Cancer epidemiology in the last century and the next decade. *Nature* 2001;411:390-5.



Finalità degli studi di epidemiologia descrittiva


- Quantificare la rilevanza dei fenomeni sanitari
- Fornire la base per predire l'impegno dei servizi sanitari
- Evidenziare l'evoluzione dei fenomeni sanitari
- Contribuire a definire priorità di intervento
- Ipotizzare relazioni tra i dati descrittivi e gli interventi sanitari o, in generale, variazioni dei determinanti

Distribuzione regionale dei tumori delle alte vie aerodigestive




I bevitori a rischio nelle indagini PASSI

Percentuale di bevitori "binge"




2008

Bevitori a rischio Vecchia definizione INRAN di "forte bevitore"
Umbria - PASSI 2008



Bevitori a rischio Nuova definizione INRAN di "forte bevitore"
Umbria - PASSI 2008



Nelle AUSL regionali non sono emerse differenze statisticamente significative per le modalità di assunzione dell'alcol ritenute a rischio anche per la limitata numerosità (range dal 10% dell'AUSL3 18% dell'AUSL1)

Studi eziologici

Modelli di studio della

- Epidemiologia analitica ed
- Epidemiologia sperimentale

Associazione e causalità

- Formazione progressiva delle evidenze
- Associazione tra esposizione ad un fattore e una malattia in studi ben disegnati ed analizzati: fattore di rischio o protettivo
- Conferme sperimentali: fattore causale

Studi epidemiologici

- Studi Osservazionali (“esperimenti naturali”)
 - Descrittivi
 - Longitudinali
 - Trasversali
 - Analitici
 - Trasversali
 - Caso-controllo
 - Coorte
 - Storico
 - Prospettico
 - Caso-coorte
- Studi sperimentali
 - Esperimenti randomizzati
 - Studi non randomizzati

Epidemiologia - definizione 2

- Studio della **distribuzione e dei determinanti di stati di salute o eventi sanitari in popolazioni** specificate e l'applicazione di questo studio al **controllo della salute**

Last JM. A dictionary of epidemiology. Oxford University press

Generalizzazione della definizione 1

- Da Malattia a stati di salute ed eventi (la comparsa di una malattia è un tipo di evento sanitario)
- Dalla descrizione della distribuzione e individuazione delle cause delle malattie (base della medicina preventiva) al controllo dei fenomeni sanitari (valutazione degli interventi sanitari: Epidemiologia clinica)

Eziologia

- “felix qui potuit rerum cognoscere causas”
(Virgilio, *Georgiche*, II, 490)
- Una delle principali finalità investigative della epidemiologia è la ricerca delle cause delle malattie
- [Possiamo facilmente estendere questo paradigma alla ricerca dei determinanti di effetti o esiti sanitari diversi dall’insorgenza di malattia]

Epidemiologia

- Eziologica


Finalizzata alla identificazione delle cause di malattia e del benessere delle popolazioni

- Clinica e valutativa


Finalizzata alla identificazione di determinanti dei risultati dei trattamenti e, in generale, del decorso della malattia nelle popolazioni dei malati

Surgical treatment by year and age class


60-69




70-79



> = 80




Treatment associated with BCS by age class (period 1998-2001)



- Axillary dissection after breast conserving surgery was frequently omitted in women ≥ 80 years old; about 30% of women in this age class were treated with BCS
- Radiotherapy use decreased with increasing age and was almost not used among the oldest old

Radiotherapy use after BCS by age class and period




Radiotherapy use:


- decreased among youngest and, particularly, oldest women
- increased among screened age groups and 70-79 years old
(largest increase)

Metodologia epidemiologica

- Ricerca e progresso in campo biomedico
 - Ragionamento biologico
 - Disegno dello studio
 - Analisi statistica



Poster



Struttura di un articolo scientifico

- Titolo
- Riassunto
- Base di partenza scientifica
- Scopo
- Casi e metodi
- Risultati
- Discussione
- Bibliografia

ORIGINAL ARTICLE

Trends in Treatment Costs for Localized Prostate Cancer *The Healthy Screenee Effect*

Steven B. Zeliadt, PhD, MPH,*† Ruth Etzioni, PhD,*† Scott D. Ramsey, MD, PhD,*†
David F. Penson, MD, MPH,*‡ and Arnold L. Potosky, PhD§

Objective: We sought to obtain estimates of trends in initial treatment costs during the prostate-specific antigen (PSA) era that account for the changing patient case-mix associated with screening.
Subjects: We used reimbursement claims for Medicare-eligible subjects diagnosed with nonmetastatic prostate cancer between 1991 and 1999. Patients were grouped by initial treatment, with 17,846 receiving radical prostatectomy (RP), 25,933 receiving external beam radiotherapy (XRT), and 4525 receiving brachytherapy (BT).
Methods: Cancer-attributable costs were computed by subtracting noncancer costs from total Medicare reimbursements among newly diagnosed cancer patients. Noncancer costs were estimated in 2 ways: (1) average costs among age-matched, cancer-free control subjects (control method) and (2) projections based on claims from subjects before diagnosis (prediagnosis method). Adjusted annual percent change in cancer-attributable costs was calculated using multivariate generalized linear models.

Results: Noncancer costs increased at a much lower rate among men prior to diagnosis (3.8% annually) than among the general Medicare population (10.9%). The 2 approaches yielded different results; RP costs declined by 2.4% annually (prediagnosis method) versus 6.2% (control method); XRT costs declined by 1.5% versus 5.8%; and BT costs declined by 4.1% versus 8.3%.

Conclusions: Because of self-selection of PSA screening, men diagnosed with prostate cancer today are now healthier overall than men in the general population and are considerably healthier than men diagnosed previously. Estimates of cancer-attributable costs that do not account for this healthy selection effect are likely to be biased. Declines in cancer-attributable treatment costs are evident

even after accounting for a healthy screenee effect, suggesting that there has been a real reduction in cancer treatment costs.

Key Words: prostate, prostatic neoplasms, costs, cancer-attributable costs, healthy screenee bias, SEER-Medicare (*Med Care* 2007;45: 154–159)

Prostate cancer is the single most expensive cancer in terms of Medicare reimbursement costs, even considering the cost of lung cancer among both men and women.¹ The majority of prostate cancer care costs are related to initial treatment. There has not been a comprehensive examination of trends in treatment costs over time since the introduction of PSA, although several studies have considered costs of individual treatments for periods of up to 4 years.² Some studies have suggested that initial treatment costs for prostate cancer have been contained by clinical care pathways and a move to performing procedures in the outpatient setting.^{3–5} However, changing technologies may have mitigated these cost containment measures.

Another explanation for observations of declining costs may be that the composition of the case population has become healthier as a result of increased prostate-specific antigen (PSA) screening, because men participating in screening tend to be relatively healthy. Registry data indicate that prostate cancer cases are now being diagnosed in patients at earlier stages of

Basi dati bibliografiche

Key bibliographic databases for biomedical sciences :Biomedical & Health Sciences :King's College London - Mozilla Firefox

File Edit View History Bookmarks Tools Help

http://www.kcl.ac.uk/iss/ir/subject/biohealth/biomeddbases.html

Text only Internal Contact Feedback Search site

KING'S College LONDON



You are here: Home > ISS > E-resources > Subject resources > Biomedical & Health Sciences

Biomedical & Health Sciences

Common Year One

Anatomy

Biochemistry

Forensic Science

Neuroscience

Nutrition & dietetics

Pharmacology

Pharmacy

Physiology

Physiotherapy

Toxicology

Key bibliographic databases for biomedical sciences

Print version

Bibliographic databases contain information about **articles published in peer-reviewed academic journals**. These may report original research (primary research articles) or may review research in a specific area (secondary review articles).

- Medline - via Ovid or PubMed
- EMBASE - via Ovid
- BIOSIS Previews - via Web of Science
- Science Citation Index - via Web of Science
- Faculty of 1000 Biology or Medicine

Userguide Key biomedical databases

Database searching techniques

To access - use the **Databases** quicklink on the right.

The Ovid web gateway

Medline and EMBASE can both be searched via the Ovid web gateway. Searches run in one database can be re-run in the other (with modifications where required because of different subject headings), or they may be cross-searched using free-text search techniques.

Quicklinks

- ISS catalogue
- ISS user guides
- Databases
- Ejournals
- NHS
- Special Collections
- A-Z of ISS
- Help and contacts
- Your comments

PAWS

- Student PCs

Online help


- Ask ISS

Connected Campus

- About Connected Campus

King's email service

- New email login
- Old email login
- Register your...



 NCBI

A service of the [U.S. National Library of Medicine](#) and the [National Institutes of Health](#)

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for prostate cancer screening [Advanced Search](#)

Limits Preview/Index History Clipboard Details

About Entrez
Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorials
New/Noteworthy 
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation
Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

To get started with PubMed, enter one or more search terms.

Search terms may be [topics](#), [authors](#) or [journals](#).

The NIH Public Access Policy May Affect You

Does NIH fund your work?

Then your manuscript must be made available in PubMed Central

How?

If you publish in one of [these journals](#), they will take care of the whole process.

If you publish *anywhere else*, deposit the manuscript in PubMed Central via one of the options described at [publicaccess.nih.gov](#).

Note: Other funding organizations, including [HHMI](#), [Wellcome Trust](#) and the [MRC](#) also require papers to be made freely available through PMC.

PubMed is a service of the [U.S. National Library of Medicine](#) that includes over 18 million citations from MEDLINE and other life science journals for biomedical articles back to 1948. PubMed includes links to full text articles and other related resources.

A service of the U.S. National Library of Medicine
and the National Institutes of Health

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search PubMed



for prostate cancer screening

Go

Clear

[Advanced Search](#)[Save Search](#)

Limits

Preview/Index


History

Clipboard

Details

Display

Summary



Show

20



Sort By



Send to



All: 43618

Review: 6040



Items 1 - 20 of 43618

Page 1 of 2181 Next

 1: [\[The density of prostate specific antigen of the transition zone as an early predictor of prostate cancer\]](#)

[No authors listed]

Vestn Khir Im I I Grek. 2008;167(6):119-21. Russian.

PMID: 19241832 [PubMed - in process]

[Related Articles](#) 2: [Intracranial dural metastases.](#)

Nayak L, Abrey LE, Iwamoto FM.

Cancer. 2009 Feb 24. [Epub ahead of print]

PMID: 19241421 [PubMed - as supplied by publisher]

[Related Articles](#) 3: [Influence of the type of neoplasm and treatment on the survival of patients with malignant spinal tumours.](#)

Kropczyński G, Gabriel A, Kusz D, Ryś J, Miszczyk L, Paściak M.

Ortop Traumatol Rehabil. 2009 Jan-Feb;11(1):29-39.

PMID: 19240681 [PubMed - in process]

[Related Articles](#) 4: [Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men.](#)

Giri VN, Egleston B, Ruth K, Uzzo RG, Chen DY, Buuyounouski M, Raysor S, Hooker S, Torres JB, Ramikie T, Mastalski K, Kim TY, Kittles R.

Also try:[▶ prostate cancer scree](#)[▶ psa prostate cancer sc](#)[▶ prostate cancer scree](#)[▶ prostate cancer scree](#)[▶ prostate cancer scree](#)**Recent Activity**

Your browsing activit



NCBI

PubMed www.ncbi.nlm.nih.gov/sites/entrez
A service of the U.S. National Library of Medicine
and the National Institutes of Health

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for prostate cancer screening [Advanced Search](#)

Limits Preview/Index History Clipboard Details

New Try the new Advanced Search
Incorporating Limits, History, Preview/Index, Details, and Citation Search

Limit your search by any of the following criteria.

Search by Author

Search by Journal

Full Text, Free Full Text, and Abstracts

Links to full text Links to free full text Abstracts

Dates

Published in the Last:

Added to PubMed in the Last:

Humans or Animals

Humans Animals


Gender

Male Female

Languages

Subsets

The left sidebar contains a vertical list of links: About Entrez, Text Version, Entrez PubMed Overview, Help | FAQ, Tutorials, New/Noteworthy (RSS), E-Utilities, PubMed Services, Journals Database, MeSH Database, Single Citation Matcher, Batch Citation Matcher, Clinical Queries, Special Queries, LinkOut, My NCBI, Related Resources, Order Documents, NLM Mobile, NLM Catalog, NLM Gateway, TOXNET, Consumer Health, Clinical Alerts, ClinicalTrials.gov, and PubMed Central.



A service of the [U.S. National Library of Medicine](#)
and the [National Institutes of Health](#)

[All Databases](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[OMIM](#)[PMC](#)[Journals](#)[Books](#)[Search](#)[PubMed](#)

for (efficacy) AND (#6) AND mortality

[Preview](#)[Go](#)[Clear](#)[Advanced Search](#)[Save Search](#)[Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)

New Try the new Advanced Search

Incorporating Limits, History, Preview/Index, Details, and Citation Search

- Enter terms and click Preview to see only the number of search results.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

[Search](#)[Most Recent Queries](#)

[#8 Search \(efficacy\) AND \(#6\) AND mortality](#)

[#7 Search \(efficacy\) AND \(#6\)](#)


[#6 Search prostate cancer screening](#)

Add Term(s) to Query or View Index:

- Enter a term in the text box; use the pull-down menu to specify a search field.
- Click Preview to add terms to the query box and see the number of search results, or click Index to view terms within a field.

[All Fields](#)[Preview](#)[Index](#)

Click **AND**, **OR**, **NOT** to add a term to the query box

A service of the U.S. National Library of Medicine
and the National Institutes of Health

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search PubMed

for (efficacy) AND (#6) AND mortality

Go

Clear

[Advanced Search](#)[Save Search](#)

Limits

Preview/Index

History

Clipboard

Details

Display

Summary

Show

20

Sort By

Send to

All: 260

Review: 58



Items 1 - 20 of 260

Page 1 of 13 Next

Recent Activity

(efficacy) AND ((pr

prostate cancer sc

 1: [Hypophysectomy for prostate cancer: a revival of old knowledge?](#)

Flitsch J, Berneuther C, Hagel C, Lüdecke DK.

J Neurosurg. 2008 Oct;109(4):760-4.

PMID: 18826367 [PubMed - indexed for MEDLINE]

[Related Articles](#) 2: [PSA use and incidence of prostate biopsy in the Tuscany region: is opportunistic screening discounting biopsy in subjects with PSA elevation?](#)

Ciatto S, Houssami N, Martinelli F, Giusti F, Zappa M.

Tumori. 2008 Jul-Aug;94(4):518-22.

PMID: 18822688 [PubMed - indexed for MEDLINE]

[Related Articles](#) 3: [Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.](#)

Ansari J, Hussain SA, Zarkar A, Tanguay JS, Bliss J, Glaholm J.

Oncol Rep. 2008 Oct;20(4):891-6.

PMID: 18813832 [PubMed - indexed for MEDLINE]

[Related Articles](#) 4: [Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.](#)

Mashkini ID, Mottram E, Clouston M, Ellard P, Marcelli I, Herkes P, DiPersio J, D'Onofrio G, Veronesi G, D'Onofrio



NCBI

PubMed www.ncbi.nlm.nih.gov/pubmed

A service of the U.S. National Library of Medicine
and the National Institutes of Health

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for Go Clear Advanced Search

Limits Preview/Index History Clipboard Details

Display AbstractPlus Show 20 Sort By Send to

All: 1 Review: 0

1: [Int J Cancer](#), 2008 Jul 15;123(2):421-9.



Recent trends in prostate cancer mortality show a continuous decrease in several countries.

Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, Schmidlin F, Miralbell R, Zanetti R.

Geneva Cancer Registry, Institute for Social and Preventive Medicine, University of Geneva, Geneva, Switzerland.

Prostate specific antigen (PSA) screening was introduced to detect prostate cancer at an early stage and to reduce prostate cancer-specific mortality. Until results from clinical trials are available, the efficacy of PSA screening in reducing prostate cancer mortality can be estimated by surveillance of prostate cancer mortality trends. Our study analyzes recent trends in prostate cancer mortality in 38 countries. We used the IARC-WHO cancer mortality database and performed joinpoint analysis to examine prostate cancer mortality trends and identified 3 patterns. In USA, and to a lesser extent in Germany, Switzerland, Canada, France, Italy and Spain, prostate cancer-specific mortality decreased to a level lower than before the introduction of PSA screening. In Australia, New Zealand, Austria, Finland, The Netherlands, Norway, United Kingdom, Hungary, Slovakia, Israel, Singapore, Sweden and Portugal, mortality from prostate cancer decreased but rates remain higher than before the introduction of PSA screening. Prostate cancer mortality continued to increase in Belgium, Denmark, Greece, Ireland, Bulgaria, Czech Republic, Belarus, Ukraine, Russian Federation, Romania, Poland, Argentina, Chile, Cuba, Mexico, Japan, China Hong Kong and the Republic of Korea. The trends in prostate cancer mortality rates in examined countries suggest that PSA screening may be effective in reducing mortality from prostate cancer. (c) 2008 Wiley-Liss, Inc.

PMID: 18452171 [PubMed - indexed for MEDLINE]

Related Articles

- ▶ International trends in prostate-cancer mortality and spreading.
- ▶ Prostate-cancer mortality in the USA and UK in study.
- ▶ Prostate cancer incidence and mortality trends Europeans.
- ▶ **Review** Detection of prostate cancer: the imp Randomized Study of Screening for Prostate C
- ▶ **Review** Patterns and trends in prostate cancer prevalence and mortality. Part I: international co

Recent Activity

- Recent trends in prostate cancer mortality in several countries...
- (efficacy) AND ((prostate... (260)

Punti chiave

- La metodologia epidemiologica rappresenta uno dei fondamenti della ricerca e dunque del progresso in campo biomedico
- L'epidemiologia si occupa tradizionalmente di quantificare i fenomeni sanitari e di indagare le cause delle malattie
- Per l'orientamento eziologico e l'approccio di popolazione l'epidemiologia è legata alla Medicina Preventiva e alla Sanità Pubblica

